Mometason Cipla (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometason Cipla, is a corticosteroid presented as a nasal spray for nasal administration. It is indicated for the treatment of inflammatory nasal conditions such as allergic rhinitis and nasal polyps, helping to reduce swelling, congestion, and nasal discharge in affected individuals.

GNH USA supplies Mometason Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company continually adheres to stringent quality standards and provides reliable logistics for global distribution.

Mometasone furoate nasal spray acts on the inflammatory pathways of the nasal mucosa to relieve symptoms of allergic and non‑allergic nasal disorders.

Allergic rhinitis: reduces nasal inflammation, congestion and itching. Seasonal allergic rhinitis: provides relief from pollen‑induced nasal symptoms. Perennial allergic rhinitis: controls year‑round nasal inflammation caused by indoor allergens. Nasal polyps: diminishes polyp size and improves nasal airflow.

Nasal administration of mometasone furoate can be associated with local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning - Headache - Epistaxis (nosebleed) - Altered taste - Throat irritation - Cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or cataract formation - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal passages

Before prescribing Mometason Cipla, clinicians should consider several precautionary measures to ensure safe use.

Pregnancy: consult a healthcare professional, as safety data are limited. Breastfeeding: discuss potential risks with a physician, as drug may pass into milk. Children: safety not established in patients under 2 years of age. Long‑term use: monitor for signs of adrenal insufficiency or ocular effects. Drug interactions: review all concomitant medications, especially systemic steroids and CYP3A4 inhibitors. Store at room temperature: keep in original container, protect from moisture and light.

Mometasone furoate may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic corticosteroids: increased risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise local exposure and side‑effect risk.

Moderate Interactions (Monitor Closely): - Antihistamines: additive local anti‑allergic effect, monitor symptom control. - Nasal decongestants: combined use may increase nasal irritation. - Live vaccines: topical steroids could theoretically reduce immune response; assess risk.